
Thulium–yttrium–aluminium–garnet (Tm: YAG) laser ablation for ≤cT1 penile cancer patients (2013-2022) yielded promising oncological outcomes. In a retrospective analysis of 71 patients, 50.5% experienced local tumor recurrence, with higher rates observed for G3 tumors. Follow-up included re-treatment with 1 to 3 Tm: YAG laser ablations, glansectomy, and partial/total penile amputation. Disease progression occurred in 7.5% of patients. Tm: YAG laser ablation emerges as a valid alternative for selected penile cancer cases.
Like
Save
Share